About-cancer/treatment/drugs/myeloproliferative-neoplasms

From loveco.care
Revision as of 21:38, 29 October 2019 by Dengjun (talk | contribs) (Marked this version for translation)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Other languages:
English

Drugs Approved for Myeloproliferative Neoplasms

This page lists cancer drugs approved by the Food and Drug Administration (FDA) for myeloproliferative neoplasms. The list includes generic and brand names. This page also lists common drug combinations used in myeloproliferative neoplasms. The individual drugs in the combinations are FDA-approved. However, drug combinations themselves usually are not approved, but are widely used.

The drug names link to NCI's Cancer Drug Information summaries. There may be drugs used in myeloproliferative neoplasms that are not listed here.

Drugs Approved for Myeloproliferative Neoplasms

Adriamycin PFS (Doxorubicin Hydrochloride)

Adriamycin RDF (Doxorubicin Hydrochloride)

Arsenic Trioxide

Azacitidine

Cerubidine (Daunorubicin Hydrochloride)

Clafen (Cyclophosphamide)

Cyclophosphamide

Cytarabine

Cytosar-U (Cytarabine)

Cytoxan (Cyclophosphamide)

Dacogen (Decitabine)

Dasatinib

Daunorubicin Hydrochloride

Decitabine

Doxorubicin Hydrochloride

Fedratinib Hydrochloride

Gleevec (Imatinib Mesylate)

Imatinib Mesylate

Inrebic (Fedratinib Hydrochloride)

Jakafi (Ruxolitinib Phosphate)

Nilotinib

Rubidomycin (Daunorubicin Hydrochloride)

Ruxolitinib Phosphate

Sprycel (Dasatinib)

Tarabine PFS (Cytarabine)

Tasigna (Nilotinib)

Trisenox (Arsenic Trioxide)

Vidaza (Azacitidine)

Drug Combinations Used in Myeloproliferative Neoplasms

ADE

Retrieved from "http://www.loveco.care/index.php?title=About-cancer/treatment/drugs/myeloproliferative-neoplasms&oldid=3590"